MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ
48.48
+0.25
+0.52%
After Hours: 49.20 +0.72 +1.49% 18:08 12/31 EST
OPEN
47.94
PREV CLOSE
48.23
HIGH
49.19
LOW
47.71
VOLUME
367.14K
TURNOVER
--
52 WEEK HIGH
52.47
52 WEEK LOW
12.21
MARKET CAP
1.34B
P/E (TTM)
-17.2000
1D
5D
1M
3M
1Y
5Y
1D
Trade Alert: Independent Director Of AnaptysBio J. Ware Has Sold Stock
Simply Wall St · 12/30/2025 10:11
Weekly Report: what happened at ANAB last week (1222-1226)?
Weekly Report · 12/29/2025 10:03
Top AnaptysBio Insider Makes Major Move With Fresh Stock Sale
TipRanks · 12/24/2025 02:02
AnaptysBio Director J. Anthony Ware Reports Sale of Common Shares
Reuters · 12/23/2025 21:30
AnaptysBio Chief Medical Officer Paul F. Lizzul Reports Disposal of Common Shares
Reuters · 12/23/2025 21:29
AnaptysBio CFO Dennis Mulroy Reports Sale of Common Shares
Reuters · 12/23/2025 21:28
AnaptysBio Chief Legal Officer Eric J. Loumeau Reports Sale of Common Shares
Reuters · 12/23/2025 21:28
Weekly Report: what happened at ANAB last week (1215-1219)?
Weekly Report · 12/22/2025 10:02
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Webull offers AnaptysBio Inc stock information, including NASDAQ: ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.